Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Rituximab (US)
Rituximab · 3 trials · 3 indications
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| Arm | Type | Description |
|---|---|---|
| Cyclophosphamide/Vincristine/Rituximab +/- Mitoxantrone | EXPERIMENTAL | All patients receive three courses of combination chemotherapy/rituximab followed by pegfilgrastim, administered at 21-day intervals. Treatment administered is as follows: cyclophosphamide 500mg/m2 IV day 1; mitoxantrone 10mg/m2 IV day 1; vincristine 1.0mg/m2 (maximum 2mg) IV day 1; prednisone 80mg PO days 1 - 5; rituximab 375mg/m2 IV day 1. |
| Name | Type | Description |
|---|---|---|
| rituximab | DRUG | - |
| doxorubicin | DRUG | - |
| cyclophosphamide | DRUG | - |
| Mitoxantrone | DRUG | Mitoxantrone |
| Vincristine | DRUG | Vincristine |
| Prednisone | DRUG | Prednisone |
| Rituximab + ACVBP regimen plus Pegfilgrastim | DRUG | - |
| Autologous stem cell transplant | PROCEDURE | - |
Inclusion Criteria: Patient with histologically proven CD20+ diffuse large B-cell lymphoma (WHO classification) Aged from 18 to 59 years. Age-adjusted International Prognostic Index equal to 1 (elevated LDH level OR stage III-IV OR ECOG status 2-3-4). Patient not previously treated. With a minimum...
Rituximab is a monoclonal antibody used in oncology for B-cell blood cancers, including diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, and untreated CD20-positive large B-cell lymphoma. It is studied in combination regimens such as ACVBP plus pegfilgrastim. Amgen Inc. (AMGN) is developing this asset, which is in Phase 3 development.
Rituximab is used in combination chemotherapy regimens for diffuse large B-cell lymphoma, including untreated CD20-positive large B-cell lymphoma and non-Hodgkin's lymphoma. It is given with agents such as ACVBP and pegfilgrastim support. The Phase 3 trial NCT00140595 compared ACVBP plus rituximab with CHOP plus rituximab in this indication.
Rituximab targets MS4A1, also known as CD20, a B-cell surface protein. As a monoclonal antibody binding agent, it binds this target on CD20-positive B cells. This mechanism underlies its use in B-cell lymphomas such as diffuse large B-cell lymphoma and non-Hodgkin's lymphoma.
Amgen Inc. (ticker AMGN) is the developer of this rituximab asset. The company is advancing it in oncology for B-cell lymphoma indications, including diffuse large B-cell lymphoma and non-Hodgkin's lymphoma, through Phase 3 clinical development.
Rituximab is in Phase 3 development for diffuse large B-cell lymphoma and related B-cell lymphoma indications. It is investigational in this program and has completed clinical trials, including the Phase 3 study NCT00140595. It is not described as approved for these uses in this development program.
Rituximab has been studied in completed trials including NCT00140595, a Phase 3 study of ACVBP plus rituximab versus CHOP plus rituximab in diffuse large B-cell lymphoma with 380 patients in Belgium and France. Other completed trials are NCT00193479 in non-Hodgkin's lymphoma and NCT00169143 in untreated CD20-positive large B-cell lymphoma.